

CITATION REPORT

List of articles citing

**TNM staging of neoplasms of the endocrine pancreas:
results from a large international cohort study**

DOI: 10.1093/jnci/djs208

Journal of the National Cancer Institute, 2012, 104, 764-77.

Source: <https://exaly.com/paper-pdf/53110472/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
398	Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors. 2012 , 6, 381-93		16
397	Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. 2012 , 47, 941-60		80
396	Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement. 2012 , 29, 127-41		101
395	Pathologic staging of tumors: pitfalls and opportunities for improvements. 2012 , 29, 103-8		7
394	Pathology - grading and staging of GEP-NETs. 2012 , 26, 705-17		48
393	Neuroendocrine tumor disease: an evolving landscape. 2012 , 19, R163-85		96
392	Aktuelle TNM-Klassifikationen neuroendokriner Tumoren. 2012 , 18, 815-824		
391	Intervention in gastro-enteropancreatic neuroendocrine tumours. 2012 , 26, 855-65		13
390	Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review. 2012 , 2012, 357475		15
389	Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. 2013 , 20, 2815-21		141
388	Understanding pancreatic pathology. 2013 , 31, 278-285		
387	Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids. 2013 , 462, 507-13		46
386	[Targeted therapies, prognostic and predictive factors in endocrine oncology]. 2013 , 74 Suppl 1, S13-22		1
385	What's New in Surgical Oncology. 2013 ,		
384	The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours. 2013 , 13, 589-93		23
383	Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors. 2013 , 31, 3776-81		42
382	Ectopic duodenal insulinoma: a very rare and challenging tumor type. Description of a case and review of the literature. 2013 , 24, 213-9		13

381	Gastroenteropancreatic neuroendocrine neoplasms: historical context and current issues. 2013 , 30, 186-96		38
380	The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas. 2013 , 40, 100-8		30
379	Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging. 2013 , 40, 23-36		71
378	Are neuroendocrine tumors going mainstream?. 2013 , 31, 404-5		12
377	Resection strategies for neuroendocrine pancreatic neoplasms. <i>Langenbeck's Archives of Surgery</i> , 2013 , 398, 431-40	3.4	14
376	Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. <i>Hpb</i> , 2013 , 15, 935-43	3.8	11
375	Problématique des marqueurs histopronostiques dans les tumeurs neuroendocrines digestives. 2013 , 15, 510-514		
374	Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin. <i>Neuroendocrinology</i> , 2013 , 98, 137-43	5.6	35
373	Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE). <i>Neuroendocrinology</i> , 2013 , 98, 156-68	5.6	53
372	Medical treatment of neuroendocrine tumours. 2013 , 20, 27-31		8
371	Zollinger-Ellison syndrome: recent advances and controversies. 2013 , 29, 650-61		54
370	Current world literature. 2013 , 18, 111-30		
369	Proposal for a standardized pathology report of gastroenteropancreatic neuroendocrine tumors: prognostic significance of pathological parameters. 2013 , 47, 227-37		11
368	Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors. 2013 , 26, 685-96		99
367	Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors. 2013 , 37, 853-9		59
366	Loss of 11p11 is a frequent and early event in sporadic nonfunctioning pancreatic neuroendocrine neoplasms. 2014 , 32, 906-12		4
365	Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up. 2014 , 99, 3060-9		41
364	Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms. <i>Neuroendocrinology</i> , 2014 , 100, 35-44	5.6	62

363	Real-world study of everolimus in advanced progressive neuroendocrine tumors. 2014 , 19, 966-74		66
362	WHO 2010 classification of pancreatic endocrine tumors. is the new always better than the old?. 2014 , 14, 539-41		14
361	Outcome of surgery for pancreatic neuroendocrine neoplasms. 2014 , 101, 1405-12		83
360	GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETS). 2014 , 170, R173-83		21
359	Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis. 2014 , 21, R121-42		60
358	Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. 2014 , 9, 273-84		130
357	Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. <i>Pancreas</i> , 2014 , 43, 212-8	2.6	38
356	Well-differentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections. 2014 , 90, 89-97		12
355	How to follow up and when to operate asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1?. 2014 , 48, 387-9		10
354	Liver transplantation for metastatic liver malignancies. 2014 , 19, 235-44		13
353	Interobserver variability for the WHO classification of pulmonary carcinoids. 2014 , 38, 1429-36		61
352	[Gastroenteropancreatic neuroendocrine tumors: what must the pathologist know and do in 2014?]. 2014 , 34, 40-50		2
351	Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors. 2014 , 25, 151-64		35
350	The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. 2014 , 25, 186-92		116
349	Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases. 2014 , 465, 49-55		24
348	Gastroenteropancreatic endocrine tumors. 2014 , 386, 101-20		27
347	Neuroendocrine tumors of the pancreas: current concepts and controversies. 2014 , 25, 65-79		99
346	Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. 2014 , 111, 1222-9		81

345	Grading the neuroendocrine tumors of the lung: an evidence-based proposal. 2014 , 21, 1-16		157
344	Gastric neuroendocrine neoplasms and related precursor lesions. 2014 , 67, 938-48		51
343	Enterhexin: a novel biomarker for pancreatic neuroendocrine tumor aggressiveness. 2014 , 99, E786-95		18
342	Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. 2014 , 14, 64		36
341	Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease. 2014 , 38, 1353-61		54
340	Histogenesis and natural history of gut neuroendocrine tumors: present status. 2014 , 25, 165-70		13
339	Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms. 2014 , 46, 9-17		18
338	Techniques for endoscopic ultrasound-guided fine-needle biopsy. 2014 , 24, 83-107		22
337	Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. 2014 , 208, 775-780		47
336	Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors. <i>Neuroendocrinology</i> , 2014 , 100, 26-34	5.6	38
335	Grading neuroendocrine tumors: are we there?. 2014 , 1, 27-30		
334	AACE/ACE disease state clinical review: pancreatic neuroendocrine incidentalomas. 2015 , 21, 546-53		10
333	Neue medikamentöse Therapien bei neuroendokrinen Neoplasien. 2015 , 10, 422-428		
332	Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems. <i>Medicine (United States)</i> , 2015 , 94, e2156	1.8	36
331	Liver-directed therapy for neuroendocrine liver metastases. 2015 , 2, 75-88		
330	. 2015 ,		1
329	Profile of lanreotide autogel and its potential in the treatment of gastroenteropancreatic neuroendocrine tumors. 2015 , 123		
328	Morphological and immunohistochemical profile of pancreatic neuroendocrine neoplasms. 2015 , 66, 176-94		5

327	Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. 2015 , 5, 119-76	67
326	Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma. 2015 , 8, 1335-40	28
325	A Single Centre Analysis of Clinical Characteristics and Treatment of Endocrine Pancreatic Tumours. 2015 , 2015, 538948	2
324	ACTH-secreting pancreatic neoplasms associated with Cushing syndrome: clinicopathologic study of 11 cases and review of the literature. 2015 , 39, 374-82	50
323	Pancreatic Neuroendocrine Neoplasms. 2015 ,	3
322	Historical Background and Epidemiology. 2015 , 1-11	
321	Classification and Staging of Pancreatic Neuroendocrine Neoplasms. 2015 , 51-61	
320	Glucagonoma. 2015 , 81-87	3
319	VIPoma. 2015 , 97-104	3
318	Pancreatic Neuroendocrine Tumors Producing GHRH, GH, Ghrelin, PTH, or PTHrP. 2015 , 125-139	1
317	Serotonin-Producing Tumor. 2015 , 117-124	1
316	Nonfunctioning Pancreatic Neuroendocrine Neoplasms (Including PP-Producing and Calcitonin-Producing Tumors). 2015 , 141-146	1
315	Surgical Therapy of Pancreatic Neuroendocrine Neoplasms. 2015 , 185-190	
314	Neuroendocrine Tumours. 2015 ,	5
313	Surgical Approach in the Treatment of Neuroendocrine Tumours. 2015 , 437-474	
312	What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?. 2015 , 32, 469-79	23
311	Efficacy and cost-effectiveness of immediate surgery versus a wait-and-see strategy for sporadic nonfunctioning T1 pancreatic endocrine neoplasms. <i>Neuroendocrinology</i> , 2015 , 101, 25-34	5.6 8
310	Pancreatic Surgery. 2015 , 44, 139-48	5

309	Pathology diagnosis of pancreatic neuroendocrine tumors. 2015 , 22, 586-93		13
308	Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors. 2015 , 157, 269-76		19
307	Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection. 2015 , 19, 152-60; discussion 160		61
306	Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors?. <i>Neuroendocrinology</i> , 2015 , 101, 45-57	5.6	15
305	Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. 2015 , 3, 895-905		65
304	Ki-67 Index and Solid Growth Pattern as Prognostic Markers in Small Intestinal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2015 , 102, 327-334	5.6	2
303	Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data. 2015 , 36, 467-78		10
302	Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature. 2015 , 11, 1275-90		16
301	[What is new in the pathology of pancreatic neuroendocrine tumors?]. 2015 , 36, 220-8		1
300	Republished: gastric neuroendocrine neoplasms and related precursor lesions. 2015 , 91, 163-73		1
299	Classification of Endocrine Tumors of the Pancreas. 2015 , 281-292		
298	TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution. <i>Medicine (United States)</i> , 2015 , 94, e660	1.8	29
297	A review on management discussions of small intestinal neuroendocrine tumors and gut carcinoids. 2015 , 2, 119-128		5
296	Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics?. 2015 , 47, 973-7		35
295	Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study. 2015 , 45, 1131-8		19
294	Pathology: Classification and Immunoprofile. 2015 , 44, 104-14		5
293	Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification. <i>BMC Surgery</i> , 2015 , 15, 49	2.3	18
292	[Tissue heterogeneity contributes to suboptimal precision of WHO 2010 scoring criteria for Ki67 labeling index in a subset of neuroendocrine neoplasms of the pancreas]. 2016 , 67, 318-331		2

291	Value of Early Check-Up of Carbohydrate Antigen 19-9 Levels for Pancreatic Cancer Screening in Asymptomatic New-Onset Diabetic Patients. <i>Pancreas</i> , 2016 , 45, 730-4	2.6	11
290	Transcriptomic Profiling of Tumor Aggressiveness in Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms. <i>Pancreas</i> , 2016 , 45, 1196-203	2.6	5
289	Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea. <i>Pancreas</i> , 2016 , 45, 941-6	2.6	30
288	[Grading of neuroendocrine tumors]. 2016 , 37, 304-13		4
287	Prediction of survival and tumor recurrence in patients undergoing surgery for pancreatic neuroendocrine neoplasms. 2016 , 113, 194-202		11
286	Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. 2016 , 11, 815-824		33
285	Imagerie des tumeurs pancréatiques endocrines. 2016 , 97, 518-536		1
284	Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. 2016 , 23, 609-617		16
283	The influence of somatostatin receptor scintigraphy during preoperative staging of non-functioning pancreatic neuroendocrine tumours. <i>Clinical Radiology</i> , 2016 , 71, 537-42	2.9	4
282	Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography. <i>Pancreas</i> , 2016 , 45, 345-54	2.6	23
281	Predictive prognostic value of local and distant recurrence of F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to World Health Organization classifications (2004, 2010). Case series study. 2016 , 29, 176-82		4
280	Molecular alterations in sporadic pancreatic neuroendocrine microadenomas. 2016 , 16, 411-5		7
279	Digestive neuroendocrine neoplasms: A 2016 overview. 2016 , 48, 829-35		14
278	Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts. 2016 , 140, 437-48		91
277	Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience. 2016 , 16, 111		36
276	Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence. 2016 , 16, 882-7		22
275	Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. 2017 , 104, 34-41		86
274	Imaging of neuroendocrine tumors of the pancreas. 2016 , 97, 1241-1257		55

273	WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine. 2016 , 23, T135-T154		15
272	Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. 2016 , 50, 61-67		64
271	F-FDG PET/CT Volumetric Parameters are Associated with Tumor Grade and Metastasis in Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease. 2016 , 23, 714-721		11
270	The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications. 2016 , 3, 203-219		16
269	Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes. 2016 , 10, 444-450		6
268	Neuroendocrine Tumors. 2016 , 473-501		
267	Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution. <i>Medicine (United States)</i> , 2016 , 95, e4213	1.8	7
266	Surgical and molecular pathology of pancreatic neoplasms. 2016 , 11, 47		74
265	Cytological features contributing to the misclassification of pancreatic neuroendocrine tumors. 2016 , 5, 266-276		3
264	Role of Staging in Patients with Small Intestinal Neuroendocrine Tumours. 2016 , 20, 180-8; discussion 188		32
263	Pathology of Neuroendocrine Tumors. 2016 , 7-12		
262	Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review. 2016 , 61, 147-53		33
261	Pancreatic neuroendocrine tumors: Nosography, management and treatment. 2016 , 28 Suppl 1, S156-62		27
260	Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 264-74	7	23
259	Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study. <i>Medicine (United States)</i> , 2016 , 95, e2836	1.8	19
258	Histopathology of NET: Current concepts and new developments. 2016 , 30, 33-43		8
257	Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape. 2016 , 18, 28		6
256	Current status of the histopathological assessment, diagnosis, and reporting of colorectal neuroendocrine tumors: A Web survey from the Japanese Society for Cancer of Colon and Rectum. 2016 , 66, 94-101		10

255	Islet Cell Tumors of the Pancreas. 2016 , 45, 83-100		14
254	[Digestive neuroendocrine tumors]. 2016 , 37, 551-60		2
253	Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. 2016 , 3, 53-66		43
252	ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. <i>Neuroendocrinology</i> , 2016 , 103, 186-94	5.6	324
251	The effect of delay in diagnosis in patients with neuroendocrine tumors. 2016 , 3, 33-39		2
250	ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. <i>Neuroendocrinology</i> , 2016 , 103, 172-85	5.6	612
249	ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2016 , 103, 153-71	5.6	712
248	Pancreatic neuroendocrine tumors: Challenges in an underestimated disease. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 101, 193-206	7	15
247	Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy. 2016 , 25, 423-37		9
246	Management of follow-up of neuroendocrine neoplasias. 2016 , 30, 129-40		6
245	Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours. 2016 , 16, 403-10		23
244	Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients. 2016 , 16, 99-105		22
243	Pathologic Classification of Neuroendocrine Neoplasms. 2016 , 30, 1-19		38
242	Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. 2016 , 27, 68-81		77
241	Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity. <i>Neuroendocrinology</i> , 2016 , 103, 345-53	5.6	52
240	Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatment. 2016 , 57, 260-70		24
239	Malnutrition Predicts Clinical Outcome in Patients with Neuroendocrine Neoplasia. <i>Neuroendocrinology</i> , 2017 , 104, 11-25	5.6	59
238	Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy. 2017 , 17, 139-145		6

237	Classification of Neuroendocrine Neoplasms. 2017 , 1-13		
236	Validation and comparison between current prognostication systems for pancreatic neuroendocrine neoplasms: A single-institution experience with 176 patients. 2017 , 161, 1235-1245		12
235	Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience. 2017 , 31, 3847-3857		18
234	Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. 2017 , 22, 409-415		25
233	Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors?. 2017 , 35, 242-253		21
232	Prognostic factors of long-term outcome in surgically resectable pancreatic neuroendocrine tumors: A 12-year experience from a single center. <i>Oncology Letters</i> , 2017 , 13, 1157-1164	2.6	8
231	Watery stools and metabolic acidosis. 2017 , 12, 487-492		2
230	Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. 2017 , 1-12		
229	Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China. <i>Oncology Letters</i> , 2017 , 13, 3163-3168	2.6	9
228	Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. 2017 , 87, 165-170		15
227	Revised nodal stage for pancreatic neuroendocrine tumors. 2017 , 17, 599-604		9
226	Prognostic relevance of UCH-L1 and Interneixin in pancreatic neuroendocrine tumors. 2017 , 7, 2205		12
225	Everolimus in Pancreatic Neuroendocrine Carcinomas G3. <i>Pancreas</i> , 2017 , 46, 302-305	2.6	37
224	Gastro-entero-pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: a therapy update. 2017 , 4, 43-58		1
223	Prognostic and predictive biomarkers in neuroendocrine tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 113, 268-282	7	33
222	Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria. 2017 , 76, 197-204		10
221	Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied. 2017 , 470, 153-164		60
220	Early Gastroenteropancreatic Neuroendocrine Tumors: Endoscopic Therapy and Surveillance. 2017 , 33, 332-338		18

219	Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors. <i>Medicine (United States)</i> , 2017 , 96, e8262	1.8	8
218	Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications. 2017 , 33, 324-330		79
217	Cyto-histology in NET: what is necessary today and what is the future?. 2017 , 18, 381-391		15
216	The future: diagnostic and imaging advances in MEN1 therapeutic approaches and management strategies. 2017 , 24, T209-T225		17
215	Épidémiologie des tumeurs neuroendocrines intestinales. 2017 , 11, 207-211		
214	Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours. 2017 , 19, 579-586		24
213	Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids. <i>Histopathology</i> , 2017 , 70, 412-422	7.3	30
212	Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. 2017 , 23, 600-609		116
211	Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. 2017 , 35, 274-280		91
210	A patient with MEN1 and end-stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation. 2018 , 8, 449-452		
209	Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel. <i>Oncotarget</i> , 2017 , 8, 93464-93475	3.3	18
208	Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up. 2017 , 13, 271-282		7
207	Pancreatic neuroendocrine tumors. 2017 , 6, 21-28		25
206	Alterations in Cancer-related Genes Associated with Grading of Well Differentiated Pancreatic Neuroendocrine Neoplasms. 2017 , 07,		
205	What's in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors. 2017 , 35, 265-267		4
204	Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis. 2018 , 18, 313-317		10
203	Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. 2018 , 117, 868-878		25
202	Current and emerging therapies for PNETs in patients with or without MEN1. 2018 , 14, 216-227		34

201	Gastroenteropancreatic Neuroendocrine Tumors. 2018 , 552-570			1
200	Assessment of the American Joint Commission on Cancer 8th Edition Staging System for Patients with Pancreatic Neuroendocrine Tumors: A Surveillance, Epidemiology, and End Results analysis. 2018 , 7, 626-634			19
199	Tumor Staging TNM. 2018 , 77-101			
198	Tumour Staging: Ileum. 2018 , 197-206			
197	Neuroendocrine Tumors in Real Life. 2018 ,			1
196	Epidemiology and Classification of Neuroendocrine Tumors of the Pancreas. 2018 , 919-929			
195	Surgical Treatment of Endocrine Tumors. 2018 , 994-1001			
194	Long-Term Outcome After Treatment of Endocrine Tumors. 2018 , 1029-1034			
193	Grading Using Ki-67 Index and Mitotic Rate Increases the Prognostic Accuracy of Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2018 , 47, 326-331	2.6		9
192	Accuracy of Pancreatic Neuroendocrine Tumour Grading by Endoscopic Ultrasound-Guided Fine Needle Aspiration: Analysis of a Large Cohort and Perspectives for Improvement. <i>Neuroendocrinology</i> , 2018 , 106, 158-166	5.6		30
191	A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. <i>Hpb</i> , 2018 , 20, 197-203	3.8		20
190	The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines. <i>Neuroendocrinology</i> , 2018 , 106, 357-365	5.6		38
189	Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). 2018 , 23, 422-432			45
188	Grade 2 pancreatic neuroendocrine tumors: overbroad scope of Ki-67 index according to MRI features. 2018 , 43, 3016-3024			4
187	Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors. 2018 , 143, 1806-1816			25
186	Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems. 2018 , 17, 169-175			12
185	Role of Minimally Invasive Surgery in the Treatment of Pancreatic Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018 , 141-147	0.1		0
184	Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. 2018 , 412, 188-193			32

183	Classification of Abdominal Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018 , 21-32	0.1	
182	[Metabolic disorders as paraneoplastic syndromes]. 2018 , 59, 114-124		0
181	Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and molecular updates. <i>Histopathology</i> , 2018 , 72, 153-167	7.3	26
180	Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?. 2018 , 472, 519-531		59
179	Hereditary Syndromes and Abdominal Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018 , 33-52	0.1	
178	Clinical Usefulness of F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms. 2018 , 23, 186-192		29
177	Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. 2018 , 472, 341-349		76
176	Pancreatic Neuroendocrine Tumours. 2018 , 173-179		
175	Challenges Staging Neuroendocrine Tumors of the Pancreas, Jejunum and Ileum, and Appendix. 2018 , 25, 591-593		10
174	Advances in the cytologic diagnosis of gastroenteropancreatic neuroendocrine neoplasms. 2018 , 126, 980-991		7
173	Lymphadenectomy in pancreatic neuroendocrine neoplasms: Why are we still debating?. 2018 , 18, 855-861		5
172	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data From a Large International Cohort Study. <i>Neuroendocrinology</i> , 2018 , 107, 375-386	5.6	52
171	[Neuroendocrine Neoplasia within the German NET Registry]. <i>Zeitschrift Fur Gastroenterologie</i> , 2018 , 56, 1237-1246	1.6	8
170	Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2018 , 47, 321-325	2.6	18
169	Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67. 2018 , 25, 2467-2474		63
168	Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. 2018 , 19, 909-928		25
167	The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. 2018 , 47, 463-470		97
166	Pancreatic Neuroendocrine Tumors (pNETs). 2018 , 129-157		

165	Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation. 2018 , 2018, 9647247		15
164	Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches. 2018 , 47, 525-548		14
163	The latest exploration of staging and prognostic classification for pancreatic neuroendocrine tumors: a large population-based study. 2018 , 9, 1698-1706		11
162	Prognostic Evaluations Tailored to Specific Gastric Neuroendocrine Neoplasms: Analysis Of 200 Cases with Extended Follow-Up. <i>Neuroendocrinology</i> , 2018 , 107, 114-126	5.6	36
161	Surgical Management of Elderly Patients. 2018 ,		2
160	Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances. 2019 , 26, 13-30		42
159	Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors \geq cm after curative resection: A multi-institutional study of 392 cases. 2019 , 120, 1071-1079		21
158	Consideration of Age Is Necessary for Increasing the Accuracy of the AJCC TNM Staging System of Pancreatic Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 2019 , 9, 906	5.3	3
157	Endoscopic ultrasound-guided fine-needle biopsy is superior to fine-needle aspiration in assessing pancreatic neuroendocrine tumors. 2019 , 7, E1281-E1287		15
156	What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms?. 2019 , 20, 5-17		46
155	Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study. 2019 , 19, 367-371		18
154	Survivals of patients with surgically treated and High-grade pancreatic neuroendocrine carcinomas: A comparative study between two American Joint Committee on Cancer 8th tumor-node-metastasis staging systems. 2019 , 45, 1054-1060		12
153	Outcomes of Lymph Node Dissection for Non-metastatic Pancreatic Neuroendocrine Tumors: A Propensity Score-Weighted Analysis of the National Cancer Database. 2019 , 26, 2722-2729		14
152	Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome. <i>BMC Cancer</i> , 2019 , 19, 362	4.8	14
151	Pancreatic neuroendocrine tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy:A retrospective cohort study in the SEER database. 2019 , 66, 103-109		8
150	A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms. 2019 , 54, 819-828		6
149	Intertumor heterogeneity in 60 pancreatic neuroendocrine tumors associated with multiple endocrine neoplasia type 1. 2019 , 14, 54		6
148	Updates of pancreatic neuroendocrine neoplasm in the 2017 World Health Organization classification. 2019 , 23, 42-47		4

147	Prognostic Validity of the American Joint Committee on Cancer Eighth Edition TNM Staging System for Surgically Treated and Well-Differentiated Pancreatic Neuroendocrine Tumors: A Comprehensive Analysis of 254 Consecutive Patients From a Large Chinese Institution. <i>Pancreas</i> , 2019 , 48, 613-621	2.6	13
146	Lymph node involvement in pancreatic neuroendocrine tumors: significance as a predictor of survival. 2019 , 2, 25-33		2
145	Pancreatic neuroendocrine tumors. 2019 , 35, 468-477		10
144	Prognostic value of negative lymph node count in patients with jejunoileal neuroendocrine tumors. 2019 , 2, 125-131		
143	New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors: A Multi-institutional and National Data Analysis. <i>Annals of Surgery</i> , 2021 , 274, e28-e35	7.8	21
142	Automated quantification of Ki-67 index associates with pathologic grade of pulmonary neuroendocrine tumors. 2019 , 132, 551-561		9
141	Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. 2019 , 79, 21-42		25
140	Systematic review of current prognostication systems for pancreatic neuroendocrine neoplasms. 2019 , 165, 672-685		11
139	Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection. 2019 , 45, 755-760		10
138	Recent advances in the diagnosis and management of pancreatic neuroendocrine tumours. 2019 , 10, 269-274		4
137	The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs): Time-trend and Outcome Analysis From 587 Consecutive Resections at a High-volume Institution. <i>Annals of Surgery</i> , 2019 , 269, 725-732	7.8	35
136	Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies. 2020 , 44, 594-603		2
135	The functioning side of the pancreas: a review on insulinomas. 2020 , 43, 139-148		13
134	The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas. <i>Neuroendocrinology</i> , 2020 , 110, 364-376	5.6	10
133	Loss of nectin-3 expression as a marker of tumor aggressiveness in pancreatic neuroendocrine tumor. 2020 , 70, 84-91		1
132	Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis. 2020 , 27, 1203-1212		13
131	Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement. <i>Neuroendocrinology</i> , 2021 , 111, 609-630	5.6	16
130	Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication. <i>Journal of Gastrointestinal Oncology</i> , 2020 , 11, 548-558	2.8	7

129	Sequence of therapy and survival in patients with advanced pancreatic neuroendocrine tumours. 2020 , 27, 215-219		
128	Classification of neuroendocrine neoplasms: lights and shadows. 2021 , 22, 527-538		12
127	A comprehensive validation of the novel 8th edition of American Joint Committee on Cancer staging manual for the long-term survivals of patients with non-functional pancreatic neuroendocrine neoplasms. <i>Medicine (United States)</i> , 2020 , 99, e22291	1.8	2
126	CUX1-Transcriptional Master Regulator of Tumor Progression in Pancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2020 , 12,	6.6	2
125	Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors. 2020 , 7, 385		1
124	Understanding the Treatment Algorithm of Patients with Metastatic Pancreatic Neuroendocrine Neoplasms: A Single-Institution Retrospective Analysis Comparing Outcomes of Chemotherapy, Molecular Targeted Therapy, and Peptide Receptor Radionuclide Therapy in 255 Patients. <i>Neuroendocrinology</i> , 2021 , 111, 263-275	5.6	2
123	World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution. <i>BMC Cancer</i> , 2020 , 20, 906	4.8	2
122	The Clinical Features and Molecular Mechanisms of ACTH-secreting Pancreatic Neuroendocrine Tumors. 2020 , 105,		7
121	mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus. <i>Cancers</i> , 2020 , 12,	6.6	5
120	Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy. 2020 , 122, 442-449		0
119	Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors. <i>Medicine (United States)</i> , 2020 , 99, e20324	1.8	4
118	Predictors of Recurrence and Survival in Patients With Surgically Resected Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020 , 49, 249-254	2.6	11
117	Validation and modification of staging Systems for Poorly Differentiated Pancreatic Neuroendocrine Carcinoma. <i>BMC Cancer</i> , 2020 , 20, 188	4.8	3
116	Predicting survival in non-functional pancreatic neuroendocrine tumours. 2020 , 90, 2026-2031		2
115	[Indications for the Surgical Management of Pancreatic Neuroendocrine Neoplasms]. 2020 , 145, 365-373		1
114	Comparison of different anti-Ki67 antibody clones and hot-spot sizes for assessing proliferative index and grading in pancreatic neuroendocrine tumours using manual and image analysis. <i>Histopathology</i> , 2020 , 77, 646-658	7.3	8
113	Survivals of patients with pancreatic neuroendocrine carcinomas: An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual. <i>Medicine (United States)</i> , 2020 , 99, e18736	1.8	3
112	CT-Radiomic Approach to Predict G1/2 Nonfunctional Pancreatic Neuroendocrine Tumor. 2020 , 27, e272-e281		11

111	Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2020 , 31, 844-860		191
110	Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges. 2020 , 1874, 188367		6
109	Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors. 2020 , 27, 3928-3936		10
108	Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors. 2021 , 28, 1614-1624		15
107	Recent Advances in Digestive Tract Tumors: Updates From the 5th Edition of the World Health Organization "Blue Book". 2021 , 145, 607-626		4
106	Predicting Metastasis Risk in Pancreatic Neuroendocrine Tumors Using Deep Learning Image Analysis. <i>Frontiers in Oncology</i> , 2020 , 10, 593211	5.3	3
105	A tool to predict survival in stage IV entero-pancreatic NEN. 2021 , 44, 1185-1192		2
104	Pancreatic Neuroendocrine Tumors. 2021 , 938-948.e4		
103	Encyclopedia of Pathology. <i>Encyclopedia of Pathology</i> , 2021 , 1-3		0
102	Poorer prognosis for neuroendocrine carcinoma than signet ring cell cancer of the colon and rectum (CRC-NEC): a propensity score matching analysis of patients from the Surveillance, Epidemiology, and End Results (SEER) database. 2021 , 36, 745-756		0
101	Pathology of Neuroendocrine Neoplasms in the Digestive System. 2021 , 35-62		1
100	Encyclopedia of Pathology. <i>Encyclopedia of Pathology</i> , 2021 , 1-6		0
99	A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms. 2021 , 18, 2166-2175		3
98	Number of Positive Lymph Nodes Is Superior to LNR and LODDS for Predicting the Prognosis of Pancreatic Neuroendocrine Neoplasms. <i>Frontiers in Endocrinology</i> , 2021 , 12, 613755	5.7	0
97	Increased neutrophil-lymphocyte ratio predicts recurrence in patients with well-differentiated pancreatic neuroendocrine neoplasm based on the 2017 World Health Organization classification. <i>BMC Surgery</i> , 2021 , 21, 176	2.3	1
96	CD47 expression and CD163 macrophages correlated with prognosis of pancreatic neuroendocrine tumor. <i>BMC Cancer</i> , 2021 , 21, 320	4.8	4
95	Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). <i>Seminars in Cancer Biology</i> , 2021 , 79, 141-141	12.7	2
94	Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. <i>Journal of Gastrointestinal Oncology</i> , 2021 , 12, 845-855	2.8	0

93	Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades. <i>Cancers</i> , 2021 , 13,	6.6	3
92	A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations. <i>Frontiers in Endocrinology</i> , 2021 , 12, 681013	5.7	2
91	Tumor Size on Microscopy, CT, and MRI Assessments Versus Pathologic Gross Specimen Analysis of Pancreatic Neuroendocrine Tumors. <i>American Journal of Roentgenology</i> , 2021 , 217, 107-116	5.4	1
90	Diagnostic and Interventional Role of Endoscopic Ultrasonography for the Management of Pancreatic Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
89	Looking for the right TNM staging system for pancreatic neuroendocrine tumors. <i>Hepatobiliary Surgery and Nutrition</i> , 2021 , 10, 382-384	2.1	1
88	Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience. <i>Endocrine</i> , 2021 , 74, 707-713	4	1
87	Alternative lengthening of telomeres phenotype predicts progression risk in non-insulinomas in a Chinese cohort. <i>Neuroendocrinology</i> , 2021 ,	5.6	
86	The value of MRI in identifying pancreatic neuroendocrine tumour G3 and carcinoma G3. <i>Clinical Radiology</i> , 2021 , 76, 551.e1-551.e9	2.9	
85	Prediction of non-functioning pancreatic neuroendocrine tumor grades with fractal analysis of preoperative contrast-enhanced computed tomography images. <i>European Journal of Radiology</i> , 2021 , 141, 109803	4.7	0
84	PD-L1 - inhibitors in neuroendocrine neoplasia: Results from a real-life study. <i>Medicine (United States)</i> , 2021 , 100, e23835	1.8	3
83	Clinicopathological characteristics of peripheral clinical stage IA lung adenocarcinoma with high Ki-67 expression.. <i>Translational Cancer Research</i> , 2021 , 10, 152-161	0.3	
82	ZollingerEllison Syndrome. 1078-1102		1
81	Neuroendocrine Tumors of the Pancreas. 2017 , 407-419		7
80	Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry. <i>Langenbeck's Archives of Surgery</i> , 2020 , 405, 145-154	3.4	7
79	Pancreatic Neuroendocrine Tumors: Update on the New World Health Organization Classification. <i>AJSP Review and Reports</i> , 2017 , 22, 233-239	0	15
78	Development and Validation of a Modified Eighth AJCC Staging System for Primary Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2020 ,	7.8	5
77	Why did they change that? Practical implications of the evolving classification of neuroendocrine tumours of the gastrointestinal tract. <i>Histopathology</i> , 2021 , 78, 162-170	7.3	5
76	Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification. <i>PLoS ONE</i> , 2015 , 10, e0143822	3.7	52

75	Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2017 , 12, e0179445	3.7	29
74	Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms. <i>PLoS ONE</i> , 2017 , 12, e0188876	3.7	18
73	A single institution's 21-year experience with surgically resected pancreatic neuroendocrine tumors: an analysis of survival and prognostic factors. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016 , 108, 689-696	0.9	13
72	Functional and non-functional pancreatic neuroendocrine tumours: ENETS or AJCC TNM staging system?. <i>Oncotarget</i> , 2017 , 8, 82784-82795	3.3	10
71	Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations. <i>Oncotarget</i> , 2019 , 10, 6260-6268	3.3	3
70	Elevated serum CA72-4 levels predict poor prognosis in pancreatic adenocarcinoma after intensity-modulated radiation therapy. <i>Oncotarget</i> , 2015 , 6, 9592-9	3.3	10
69	Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. <i>World Journal of Gastroenterology</i> , 2015 , 21, 9512-25	5.6	74
68	Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage. <i>World Journal of Gastroenterology</i> , 2017 , 23, 275-285	5.6	29
67	Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. <i>World Journal of Gastroenterology</i> , 2020 , 26, 2305-2322	5.6	22
66	Update on pancreatic neuroendocrine tumors. <i>Gland Surgery</i> , 2014 , 3, 258-75	2.2	59
65	Risk factors for aggressive nonfunctional pancreatic neuroendocrine tumors and the role of endoscopic ultrasound guided fine-needle aspiration. <i>Endoscopic Ultrasound</i> , 2016 , 5, 49-54	3.6	9
64	EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: Who should we treat?. <i>Endoscopic Ultrasound</i> , 2019 , 8, 220-226	3.6	24
63	Validation of the 8th AJCC Cancer Staging System for Pancreas Neuroendocrine Tumors Using Korean Nationwide Surgery Database. <i>Cancer Research and Treatment</i> , 2019 , 51, 1639-1652	5.2	16
62	PROGNOSTIC FACTORS IN PATIENTS WITH SURGICAL RESECTION OF PANCREATIC NEUROENDOCRINE TUMOURS. <i>Acta Endocrinologica</i> , 2018 , 14, 389-393	0.9	5
61	Non-functioning pancreatic neuroendocrine tumors: Surgery or observation?. <i>World Journal of Gastrointestinal Endoscopy</i> , 2017 , 9, 153-161	2.2	14
60	Surgical management of pancreatic neuroendocrine neoplasms. <i>Annals of Saudi Medicine</i> , 2014 , 34, 1-5	1.6	6
59	Stage predictivity of neutrophil/lymphocyte and platelet/lymphocyte ratios in pancreatic neuroendocrine tumors. <i>Turkish Journal of Surgery</i> , 2020 , 36, 1-8	0.6	2
58	Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: Possible clinical impact of misclassification. <i>Endoscopic Ultrasound</i> , 2021 , 10, 372-380	3.6	2

57	Prediction of recurrence after surgery based on preoperative MRI features in patients with pancreatic neuroendocrine tumors. <i>European Radiology</i> , 2021 , 1	8	0
56	Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). <i>Experimental and Therapeutic Medicine</i> , 2021 , 22, 1479	2.1	1
55	Patterns and predictors of pancreatic neuroendocrine tumor prognosis: Are no two leaves alike?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 167, 103493	7	1
54	Endocrine System. 2013 , 65-76		
53	Onkologische Therapie bei Metastasen endokriner Pankreastumoren. 2013 , 249-255		
52	New Knowledge in the Diagnosis and Medical Treatment of Pancreatic Neuroendocrine Tumors. 2013 , 127-141		
51	Surgical Therapy. <i>Updates in Surgery Series</i> , 2013 , 109-116	0.1	
50	How to Perform EUS-Guided Fine-Needle Biopsy. 2015 , 294-309		
49	Endokrines Pankreas. 2016 , 815-853		
48	Insulinoma: Literature Review (Part 1). <i>Endocrinology&Metabolism International Journal</i> , 2015 , 2,	0	
47	Neuroendocrine Tumors of the Pancreas. 1782-1807		
46	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. 2016 , 1-27		
45	Intraductal Growth of a Pancreatic Glucagonoma. <i>Japanese Journal of Gastroenterological Surgery</i> , 2016 , 49, 216-224	0.1	1
44	Neuroendocrine Tumor Classification Systems: Grading. 2016 , 3-19		
43	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. 2017 , 1-27		
42	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. 2017 , 1-27		
41	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. 2017 , 749-775		
40	Pathology of Neuroendocrine Neoplasms: Morphological, Immunophenotypical, and Circulating Molecular Markers. 2018 , 13-38		

39	Therapy for Locoregional Disease: Pancreas. 2018 , 235-254		
38	Cystic tumors of the pancreas. An update of the surgical experience in a single institution. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 87-93	0.9	0
37	Pancreatic Neuroendocrine Tumours. 2018 , 333-343		
36	Neuroendocrine tumors of the pancreas: etio-pathogenesis, diagnosis, current treatment. <i>Annals of HPB Surgery</i> , 2018 , 23, 100-110	0.4	1
35	Validation and Modification of Staging Systems for Poorly Differentiated Pancreatic Neuroendocrine Carcinoma .		
34	Validation and proposed modification of the 8th edition American Joint Committee on Cancer staging system for patients with esophageal neuroendocrine neoplasms: Evaluation of a revised lymph node classification. <i>Oncology Letters</i> , 2020 , 19, 4122-4132	2.6	1
33	Validation of the Novel Eighth Edition of American Joint Committee on Cancer Staging Manual: An In-depth Analysis for Nonfunctional Pancreatic Neuroendocrine Neoplasms. <i>Pancreas</i> , 2020 , 49, e42-e43 ^{2.6}		
32	Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 321-334	4.1	2
31	Endocrine Neoplasia. 2021 , 321-354		
30	Pancreas; Endocrine Tumors. 2020 , 10-23		
29	Validation and Modification of Staging Systems for Poorly Differentiated Pancreatic Neuroendocrine Carcinoma.		
28	Validation and Modification of Staging Systems for Poorly Differentiated Pancreatic Neuroendocrine Carcinoma.		
27	A rare case report of surgical treatment of pancreatic VIPoma. <i>Annals of HPB Surgery</i> , 2020 , 25, 113-118	0.4	
26	Prognostic validity of the American joint committee on cancer eighth edition staging system for well-differentiated pancreatic neuroendocrine tumors. <i>Hpb</i> , 2021 ,	3.8	0
25	Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment. <i>World Journal of Gastrointestinal Oncology</i> , 2020 , 12, 705-718	3.4	2
24	Grading of EUS-FNA cytologic specimens from patients with pancreatic neuroendocrine neoplasms: it is time move to tissue core biopsy?. <i>Gland Surgery</i> , 2014 , 3, 222-5	2.2	9
23	A Modified T-stage Classification for Gastric Neuroendocrine Tumors. <i>Journal of Surgical Research</i> , 2021 , 270, 486-494	2.5	
22	Progress in the Management of Pancreatic Neuroendocrine Tumors. <i>Annual Review of Medicine</i> , 2021 ,	17.4	0

21	[Indications for the surgical management of pancreatic neoplasms]. <i>Zeitschrift Fur Gastroenterologie</i> , 2021 ,	1.6	0
20	Pathology of Pancreatic Neuroendocrine Tumors. 2021 , 1-43		
19	Enhanced computed tomography features predict pancreatic neuroendocrine neoplasm with Ki-67 index less than 5.. <i>European Journal of Radiology</i> , 2021 , 147, 110100	4.7	
18	A model for predicting the overall survival of gastroenteropancreatic neuroendocrine neoplasms after surgery.. <i>Scandinavian Journal of Gastroenterology</i> , 2022 , 1-8	2.4	1
17	Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series.. <i>Medicine (United States)</i> , 2022 , 101, e28610	1.8	1
16	Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature.. <i>International Journal of Endocrinology</i> , 2022 , 2022, 6283706	2.7	
15	Fate of Surgical Patients with Small Nonfunctioning Pancreatic Neuroendocrine Tumors: An International Study Using Multi-Institutional Registries.. <i>Cancers</i> , 2022 , 14,	6.6	0
14	The link between menin and pleiotrophin in the tumor biology of pancreatic neuroendocrine neoplasms.. <i>Cancer Science</i> , 2022 ,	6.9	
13	Development and Validation of a Novel Radiomics-Based Nomogram With Machine Learning to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors.. <i>Frontiers in Oncology</i> , 2022 , 12, 843376	5.3	1
12	Evaluation of the Significance of Lymphatic, Microvascular and Perineural Invasion in Patients With Pancreatic Neuroendocrine Neoplasms.. <i>Cancer Diagnosis & Prognosis</i> , 2022 , 2, 150-159		
11	Gastrinoma. <i>Encyclopedia of Pathology</i> , 2022 , 1-4	0	
10	An Overview of Pancreatic Neuroendocrine Tumors.		
9	Image_1.TIF. 2019 ,		
8	Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging. <i>Histology and Histopathology</i> , 2021 , 36, 367-382	1.4	1
7	Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are. <i>World Journal of Gastroenterology</i> , 2022 , 28, 3258-3273	5.6	0
6	Pathology of Pancreatic Neuroendocrine Tumors. 2022 , 639-681		0
5	Gastrinoma. 2022 , 303-307		0
4	Insulinoma. 2022 , 438-440		0

- 3 Neuroendocrine Tumors of the Pancreas, Well-Differentiated (PanNET Grade 1,2,3). **2022**, 154-159 ○
- 2 Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future. **2023**, 34, 79-97 ○
- 1 Diagnostic work-up and advancement in the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. 10, ○